Hologic Receives CE Mark for Three-in-One Omni Hysteroscope in Europe
Hologic, Inc. (Nasdaq: HOLX) announced today that it has received a CE mark in Europe for its Omni™ hysteroscope, an innovative three-in-one modular scope with advanced visualization capabilities designed for both diagnostic and therapeutic hysteroscopic procedures. Obstetricians and gynecologists (ObGyns) can use the new Omni hysteroscope in out- and in-patient settings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190304005177/en/
Omni™ hysteroscope (Graphic: Business Wire)
“Experts agree that direct visualization of the uterine cavity in women with abnormal uterine bleeding is the gold standard that allows ObGyns to accurately identify and collect quality samples and remove pathology – in a safer and more effective manner than blind biopsy and curettage,”1 said Edward Evantash, M.D., Medical Director and Vice President of Global Medical Affairs, Hologic. “Featuring three easily interchangeable sheaths in one scope, our new Omni scope gives ObGyns excellent visualization capabilities with the convenience of seeing and treating pathology in a more streamlined procedure.”
The Omni scope is designed to help ObGyns simplify the process of diagnosing and treating patients. Often, a surgeon requires a diagnostic scope to look in the uterine cavity for fibroids or polyps, then switches to an operative scope to biopsy or treat the pathology. With the new Omni scope, ObGyns can use the same scope with different sheath options to conveniently see and treat pathology.2
Additional features include:2
- Premium MyoSure optics for quality visualization and clarity throughout the procedure.
- Sheaths designed with smaller diameters (3.7 mm diagnostic sheath; 5.5 mm operative sheath; 6 mm operative sheath) to reduce dilation required and promote patient comfort and easy insertion.
- Long 200 mm working length facilitates easier access and treatment for obese patients.
- Simple assembly and disassembly so sheaths can be changed out easily between procedures.
- Operative sheaths can be used with Hologic’s Aquilex™ hysteroscopic fluid management system.
- Compatible with all MyoSure ® tissue removal offerings including MyoSure REACH, MyoSure XL, MyoSure LITE, and MyoSure MANUAL devices.
“We continue to drive innovation designed with both our customers and the women they treat in mind,” said Jan Verstreken, Regional President, EMEA and Canada, Hologic. “Our customers are under pressure to deliver high-quality care to their patients in innovative ways. Our new Omni Hysteroscope provides them with a pioneering device that can treat a diverse range of patients.”
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, MyoSure, Omni, The Science of Sure, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners.
Important Safety Information
The Omni™ hysteroscope is intended to provide viewing of the cervical canal and uterine cavity for the purpose of performing diagnostic and operative procedures. The Omni hysteroscope is not appropriate for patients who are exhibiting acute pelvic inflammatory disease or exhibit the following conditions: inability to distend uterus, cervical stenosis, cervical/vaginal infection, uterine bleeding or menses, invasive carcinoma of the cervix, recent uterine perforation, medical contraindications, or intolerance to anesthesia. For detailed benefit and risk information, please consult the Instructions for Use.
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to firstname.lastname@example.org.
|1.||Salim S, et al. Diagnosis and Management of Endometrial Polyps: A Critical Review of the Literature. J Minim Invasive Gynecol, 2011;18(5):569-581|
|2.||Omni hysteroscope Instruction for Use. October 2018.|
SOURCE: Hologic, Inc.
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Results Are In! BOC Group Named a Leader in the Enterprise Architecture Management Suites, Q1 2019 report by Independent Research Firm25.3.2019 13:32:00 CET | Pressemelding
BOC Group, the leading global provider of Enterprise Management Solutions, announced today that it has been recognized as a “Leader” in The Forrester Wave™: Enterprise Architecture Management Suites, Q1 2019 report. Evaluated against 35 rigorous criteria, BOC Group’s EA suite ADOIT received the highest possible scores in 16 of them, including customer satisfaction, innovation agenda criteria and many others! Christoph Moser, ADOIT product manager, comments on this accomplishment by saying: “We see this achievement as an affirmation of our unwavering position as a front-runner in the EA industry and a direct reflection of the strength, depth and breadth we have incorporated across all aspects of our comprehensive, user-centric EA offering and portfolio in the last years.” Moser continues: “For us, this recognition is hard-earned and well deserved. But more importantly, we believe it further proves our strategy, relentless commitment to our customers, and continued mission to enable orga
ResMed Launches Next-generation ReSupply Solution25.3.2019 13:00:00 CET | Pressemelding
ResMed (NYSE: RMD) (ASX: RMD) today launched its automated ResMed ReSupply solution for all U.S. home medical equipment (HME) providers to increase sleep apnea patients’ long-term therapy adherence and improve patient satisfaction. Patients enrolled in an automated resupply program are 50 percent less likely to stop PAP (positive airway pressure) therapy within the first year, according to a 2018 study. ResMed’s program goes one step further, automating enrollment as patients meet compliance requirements and letting patients choose their preferred contact method – text, email or live call. Patients can also order supplies through a web- or mobile-based patient portal. HMEs are able to manage all their patients’ resupply needs from a single comprehensive dashboard so they can quickly identify, prioritize and assign tasks. “The new resupply platform is simple and easy to use – everything you need is at your fingertips,” said Kera Tennyson, a PAP location manager at Advanced Medical Solut
Sigma Systems Named Finalist for 4 Industry Awards25.3.2019 12:00:00 CET | Pressemelding
Sigma Systems, the global leader in catalog-driven software, today announced that it has been named as a finalist for two TM Forum Excellence Awards and as a semi-finalist for two Pipeline Innovation Awards. The TM Forum’s Excellence Awards highlight companies and individuals that demonstrate commitment to the evolution of the industry through digital transformation and the adoption of best practices and standards that TM Forum delivers through its Collaboration Community. Sigma is a finalist in the Service Innovator of the year and Catherine Michel is a finalist for the CTO of the Year – an award that she won in 2018. Nik Willetts, CEO, TM Forum said “Congratulations to the finalists of the TM Forum Excellence Awards 2019. As ever, the quality of the competition this year was incredibly high. With 5G fast approaching and pressure to digitally transform intensifying, it’s great to see these organizations pave the way for change and transformation. We’re excited and proud to work alongs
Newmont Announces Conditional Special Dividend25.3.2019 11:55:00 CET | Pressemelding
Newmont Mining Corporation (NYSE: NEM) (Newmont or the Company) today announced that its Board of Directors declared a one-time special dividend of $0.88 per share of common stock, conditional upon approval of the Goldcorp Inc. (NYSE: GG) (TSX: G) (Goldcorp) transaction. The dividend will be paid to Newmont shareholders of record as of April 17, 2019 (the record date), which is prior to closing of the proposed Newmont Goldcorp combination. The special dividend is conditional upon the approval by both Newmont’s and Goldcorp’s shareholders of the resolutions to be considered at their shareholder meetings on April 11 and April 4, 2019, respectively, in connection with the proposed transaction. The special dividend will be paid, subject to satisfaction of the conditions, on May 1, 2019. Closing of the Newmont Goldcorp transaction is expected shortly after the two shareholder special meetings if shareholders of both companies approve the resolutions. The special dividend delivers value to e
Tradeweb Markets Commences Roadshow for Initial Public Offering25.3.2019 11:30:00 CET | Pressemelding
Tradeweb Markets, a leading, global operator of electronic marketplaces for rates, credit, equities and money markets, today announced that it has commenced the roadshow for the initial public offering of its Class A common stock. Tradeweb Markets is offering 27,268,767 shares of its Class A common stock at an initial public offering price between $24.00 and $26.00 per share. Tradeweb Markets expects to grant the underwriters a 30-day option to purchase up to an additional 4,090,315 shares of Class A common stock at the initial public offering price, less the underwriting discounts and commissions. The shares are expected to trade on the NASDAQ Global Select Market under the ticker symbol "TW." Tradeweb intends to use the net proceeds from the offering to purchase equity interests from certain existing bank stockholders. Refinitiv will continue to own a controlling interest in Tradeweb following the offering. J.P. Morgan, Citigroup, Goldman Sachs & Co. LLC and Morgan Stanley are acting
GeoSpock and X-Locations Collaborate to Deliver Next Generation Location Data Analysis in Japan25.3.2019 11:00:00 CET | Pressemelding
GeoSpock® – the extreme-scale spatial big data integration company that provides analytics, builds insight, and enables predictions across space and time – today announced a new partnership with X-Locations – the Japan-based location AI platform company. The companies will be collaborating on a series of projects in Japan to raise awareness of the importance of location intelligence, as well as to demonstrate how and why we should be leveraging this data. The partnership will see X-Locations integrate GeoSpock’s unique spatial big data platform – which offers extreme geospatial scale and the hyper-efficient retrieval of data – into their products to improve speed of query, increase scale capacity, and reduce cost. Through the utilisation of artificial intelligence (AI) and machine learning, X-Locations accelerates the analysis and visualisation of big spatial data, enabling clients to make smarter decisions across multiple industries, including retail, real estate, manufacturing, and f